Teladoc Health

TDOC

Market cap $1.35B

Teladoc (TDOC) reported earnings 30 days ago. What's next for the stock?

NEW YORK, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Teladoc Health (NYSE: TDOC), the global leader in virtual care, today announced that Chuck Divita, chief executive officer, will participate in the 37th Annual Piper Sandler Healthcare Conference in New York on Tuesday, December 2, 2025, at 12:30 p.m. ET. A live audio webcast and replay of the presentation will be available at http://ir.teladochealth.com/news-and-events/events-and-presentations/.

TDOC's steady stream of acquisitions is expanding its global reach and lifting growth across key segments in 2025.

TDOC and LFMD face contrasting paths as telehealth demand climbs, with fundamentals and growth plans shaping which stock stands out.

Telehealth is not the new healthcare in 2025, but it has become an integrated and essential part of the healthcare landscape, transforming delivery, access, and convenience. First off, some legislation.

Investment firm Oracle Investment Management increased its Teladoc Health holdings by 324,416 shares, adding an estimated $2.13 million in value. The trade represents a 1.58% increase relative to the fund's 13F reportable assets under management.

Teladoc Health deepens its virtual care reach by adding TytoCare's at-home exam tech to Primary360 and 24/7 Care starting in 2026.

TytoCare's FDA-cleared home diagnostic technology will be integrated with Teladoc Health's Primary360 and 24/7 Care  programs, expanding high-quality remote care capabilities in-home capabilities   NEW YORK , Nov. 18, 2025 /PRNewswire/ -- TytoCare, the leading virtual care company enabling in-home, clinical-grade physical exams, today announces an integration with Teladoc Health (NYSE: TDOC), the global leader in virtual care. This collaboration integrates TytoCare's Home Smart Clinic with Teladoc Health's 24/7 Care and Primary360 primary care programs, using advanced home diagnostic technology to provide clinical insights to virtual care clinicians.

TDOC accelerates global growth as expanding international operations and rising overseas revenues bolster its profitability outlook.

Teladoc Health continues to see declining revenues and limited growth catalysts, with Q3 results showing a 2.2% YoY revenue decline. TDOC's recent acquisitions, including UpLift and Catapult Health, have not meaningfully offset declining user numbers or driven innovation. Despite trading at a low valuation near $7 and just 5x adjusted EBITDA, persistent growth struggles make TDOC a potential value trap.